Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson’s disease
- 7 October 2023
- journal article
- review article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 141, 106906
Abstract
No abstract availableKeywords
This publication has 139 references indexed in Scilit:
- Characterization of TAE684 as a potent LRRK2 kinase inhibitorBioorganic & Medicinal Chemistry Letters, 2012
- Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsACS Chemical Neuroscience, 2012
- LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in miceHuman Molecular Genetics, 2011
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localizationBiochemical Journal, 2010
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseNature Medicine, 2010
- Membrane Localization of LRRK2 Is Associated with Increased Formation of the Highly Active LRRK2 Dimer and Changes in Its PhosphorylationBiochemistry, 2010
- Rab GTPases as coordinators of vesicle trafficNature Reviews Molecular Cell Biology, 2009
- Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2Biochemical and Biophysical Research Communications, 2009
- Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPaseProceedings of the National Academy of Sciences, 2008